Antiplatelet Therapy

High Insulin Resistance Blunts the Superiority of Ticagrelor Over Clopidogrel in Minor Stroke Patients with CYP2C19 Mutations

By MedXY 01/22/2026

A post hoc analysis of the CHANCE-2 trial suggests that the clinical benefit of ticagrelor over clopidogrel for secondary stroke prevention in CYP2C19 loss-of-function carriers is significantly attenuated in patients with high insulin resistance.

Cardiology Internal Medicine news

Aspirin vs. Clopidogrel Beyond 30 Days Post-PCI: Equivalent Outcomes Regardless of Oral Anticoagulation Status

By MedXY 01/18/2026

A subgroup analysis of the STOPDAPT-3 trial reveals that aspirin and clopidogrel offer similar cardiovascular protection and bleeding safety between 1 month and 1 year post-PCI, regardless of whether patients are also receiving oral anticoagulation.

Cardiology news

Ticagrelor vs. Twice-Daily Clopidogrel in STEMI: Insights from the TADCLOT Trial

By MedXY 01/17/2026

The TADCLOT trial compared ticagrelor to twice-daily clopidogrel in 2,201 STEMI patients post-PCI. While ticagrelor showed no 30-day superiority in MACE reduction, it demonstrated a significant benefit within the first two weeks with comparable safety profiles between both regimens.

Cardiology Internal Medicine news

Guided Antiplatelet De-escalation Proves Safe in High Atherothrombotic Risk ACS Patients: Insights from TROPICAL-ACS

By MedXY 01/02/2026

Post-hoc analysis of the TROPICAL-ACS trial demonstrates that platelet function testing-guided de-escalation of dual antiplatelet therapy from prasugrel to clopidogrel is safe and effective in ACS patients, regardless of their atherothrombotic risk profile, offering a viable strategy for individualized care.

Cardiology Clinical Updates news

Ticagrelor Plus Aspirin Versus Aspirin Alone After Coronary Artery Bypass Grafting in Acute Coronary Syndrome: A Contemporary Evidence Synthesis

By MedXY 12/18/2025

This review synthesizes current evidence on the efficacy and safety of ticagrelor combined with aspirin compared to aspirin alone following CABG for acute coronary syndrome, highlighting the 2025 TACSI trial and its implications for clinical practice.

Cardiology Neurology news

No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Stroke in Patients with Atrial Fibrillation and Atherosclerosis: Results from the ATIS‑NVAF Randomized Trial

By MedXY 12/12/2025

In older patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic cardiovascular disease, adding a single antiplatelet agent to anticoagulation did not reduce ischemic events but markedly increased bleeding, providing no net clinical benefit versus anticoagulant monotherapy.

Cardiology news

Clopidogrel versus Aspirin for Secondary Prevention in Coronary Artery Disease: A Comprehensive Meta-Analysis

By MedXY 10/11/2025

This meta-analysis of nearly 29,000 CAD patients shows clopidogrel monotherapy reduces major cardiovascular events more than aspirin without increasing major bleeding risk, supporting clopidogrel as preferred secondary prevention.

Cardiology Clinical Updates

Evaluating Aspirin-Free Therapy Versus Dual Antiplatelet Treatment Post-Coronary Stenting: Insights from the STOPDAPT-3 Trial

By MedXY 09/23/2025

The STOPDAPT-3 randomized trial compared aspirin-free low-dose prasugrel monotherapy with standard dual antiplatelet therapy, revealing noninferior cardiovascular outcomes but no reduction in major bleeding after PCI, with signals of increased coronary events in the aspirin-free group.

Cardiology Clinical Updates news

Aspirin vs. Clopidogrel Monotherapy Following PCI: Insights from the STOPDAPT-3 1-Year Follow-up

By MedXY 09/22/2025

The STOPDAPT-3 trial compared aspirin and clopidogrel monotherapy after short dual antiplatelet therapy in PCI patients, showing similar cardiovascular and bleeding outcomes at 1 year.

Clinical Updates Neurology news Specialties

Antiplatelet vs Anticoagulant Therapy in Embolic Stroke of Undetermined Source: Insights from a Large Multicenter Cohort Study

By MedXY 08/17/2025

This study found no overall advantage of anticoagulation over antiplatelet therapy in ESUS patients but identified a potential benefit of anticoagulation in those with left ventricular injury.

Cardiology Clinical Updates news Specialties

Abelacimab vs. Rivaroxaban in Atrial Fibrillation Patients on Antiplatelet Therapy: Insights from the AZALEA-TIMI 71 Trial

By MedXY 08/16/2025

The AZALEA-TIMI 71 trial shows abelacimab, a novel factor XI inhibitor, reduces bleeding risk compared to rivaroxaban in atrial fibrillation patients on antiplatelet therapy, suggesting a safer anticoagulation alternative.